Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words

Updated on 4/12/2022

Final Approved Version

The complex and rapid deluge of scientific information, absence of a collaborative, open environment to produce transformative innovation, and dearth of alternative ways to disseminate scientific findings has led to major operational inefficiencies in the biomedical and pharma industries, to the tune of billions of dollars per year. These issues have driven the need for a more context-aware architecture for knowledge and scientific discourse within the biomedical arena. LPBI’s proprietary curation method and body of content decreases the time invested in the assessment of current trends, adding multiple insights. The LPBI method, delivers insights from a major body of the scientific community on multiple WEB 2.0 platforms, and makes use of new computational and Web-based tools to provide interoperability of data.

Our Ideas are Products of our Environment

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has been developing a strategy for the facilitation of Global access to Biomedical knowledge rather than the access to sheer search results on Scientific subject matters in the Life Sciences and Medicine. According to the founder and Chief Editor Aviva Lev-Ari, PhD, RN , “for the methodology to attain this complex goal the task at hand requires popularizing ORIGINAL Scientific Research via Curation of the Scientific Research Results by Experts, Authors, Writers providing expert interpretation of the original primary research results to deliver a sum greater than its parts.

LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas performed by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields. This curative process of a new formulation of clinical interpretations is establishing new conceptual connections across publications and produces new transformative ideas.

Using our curation methodology, LPBI has produced an open-access online scientific journal, a series of 18 BioMed e-books, and real-time press coverage of scientific conferences, all of which are optimally designed for novel Text Analysis methods using leading AI, ML and NLP algorithms from 3rd parties’ software, customized for classification and clustering of the Semantics in LPBI’s contents: Journal articles (6,100+) e-Books (18) Conferences content (100+). We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/

We are seeking investors looking for transfer of ownership of our Intellectual Property Assets, consisting of ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences.  These offerings are available in English and Spanish, with the opportunity for seamless translation to over 18 languages.

Through use of AI, ML, NLP, biological images with text legends, Audio Podcasts and additional modern content processing technology, we are postulating revenues on the order of $50MM to the acquirer by exploiting our content.

Versions by members of the Team

• Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

My proposed Elevator Pitch

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 18 books have been downloaded ~135,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

• Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
• From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
• From Open Access we will transition to Blockchain transaction networks.
• From Digital Cloud-based biographies we will create audio and video Podcasts
• From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships

Our Transformational transition is two dimensional:

1. Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia. Currently the Table of Contents of 18 books is being translated into Spanish for the 22 Countries speaking Spanish.
2. Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.

We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/

• Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences

My proposed Elevator Pitch

1. Strong scientific curation  makes basic research readily available to wide range of scholars, practitioners and students in biomedical science

2. The books are convenient and comprehensive compendia of the latest scholarship.

3. The updating methodology keeps material current

4. Reporting on conferences and meetings gives the audience early access to the latest technologies in biomedicine

5. Curation methodology is transferable across disciplines and languages allowing for big international and interdisciplinary markets

6. The pricing analysis has been carefully researched across multimedia platforms

• Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology

My proposed Elevator Pitch

The complex and rapid deluge of scientific information, absence of a collaborative, open environment to produce transformative innovation, and dearth of alternative ways to disseminate scientific findings has led to major operational inefficiencies in the biomedical and pharma industries, to the tune of millions of dollars per year. These issues have driven the need for a more context-driven architecture for knowledge and discourse within the biomedical arena.  The process of curation decreases time for assessment of current trends adding multiple insights, analyses WITH an underlying METHODOLOGY, provides insights from WHOLE scientific community on multiple WEB 2.0 platforms, and makes use of new computational and Web-based tools to provide interoperability of data, reporting of findings.

Our Ideas are Products of our Environment

At Leaders in Pharmaceutical Business Intelligence (LPBI) Group website owner and Editor-in-Chief,  Aviva Lev-Ari, PhD, RN has been developing a strategy for the

facilitation of Global access to Biomedical knowledge rather than the access to sheer search results on Scientific subject matters in the Life Sciences and Medicine”. According to Aviva, “for the methodology to attain this complex goal it is to be dealing with popularization of ORIGINAL Scientific Research via Content Curation of Scientific Research Results by Experts, Authors, Writers using the critical thinking process of expert interpretation of the original research results.

LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff.  It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields. This curative process establishes new connections and produces new and transformative ideas.

Using our curation methodology, LPBI has produced an open-access online scientific journal, a series of 16 BioMed e-books, and Real-time press coverage of scientific conferences, all of which are optimally designed for novel Text Analysis methods using leading AI, ML and NLP algorithms from 3rd parties software applied on LPBI’s own content customizing the applications for the needs developed by LPBI in the classification and clustering of the Semantics in our contents: Journal articles (6,000) e-Books (16) Conferences content (100).

Through use of AI, ML, NLP, Audio Podcasts and additional modern technology, we are postulating revenues on the order of $50MM to the acquirer by exploiting our content.

• Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

My proposed Elevator Pitch

Currently, there is a digital information explosion in both the Life Sciences and Medical arenas. Tracking new information and discoveries, while guarding against obsolescence, is a major challenge for scientists working in these fields.

To overcome these challenges, the Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.

LPBI (previously an equity sharing, non-profit entity) is now making its intellectual and digital intellectual properties available for sale to outside entities that are willing to take over and extend our reach.

Through use of AI, NLP, Audio Podcasts and additional advanced Machine Learning technologies, we are postulating revenues on the order of $50MM to the acquirer by exploiting our content

LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields.

This enables the LPBI Group to respond to the needs of our scientific audiences, guarding against information obsolescence and overload, through innovative digital technologies and solutions, via:

• An open-access online scientific journal
• A series of 16 BioMed e-books.
• Real-time press coverage with real-time Twitter posting of speakers quotes during conferences.

These have been made widely available to the scientific and non-research community by the Open Access feature of LPBI’s Journal’s website PharmaceuticalIntelligence.com.

• Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author

My proposed Elevator Pitch

The Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.

The effort filled a major need for information technology by the development, refinement and fulfillment of CURATION, which combines literature review, experience, and expertise into a guided-tour of accomplishments and pathways for understanding current issues in biology, chemistry, medicine and therapeutics, identifying opportunities and seizing leadership in the development and utilization of therapeutic opportunities. Through practice, recruitment, and refinement of methods, a large body of information and information management technology was amassed, along with a large following. This body of informatics and methodology is now available for commercial use to own, nurture and grow a valuable audience.

The available material includes:

• An open-access online scientific journal
• A series of 16 BioMed e-books.
• Unique coverage of speakers quotes during conferences.
• Curated cumulative knowledge organized as a path to leadership

The reach includes video and audio podcasts as well as a unique annotated chain of web links that expedites comprehensive mastery of biologic, medical, and pharmaceutical curriculum. The curation overcomes limitations of publication bias to bring the viewers to the leading edge of capabilities pointing to opportunities ripe for the exciting future.

• Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases

My proposed Elevator Pitch

• Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery

My proposed Elevator Pitch

Our world is full of device screens, we keep them in our hands (hand-held devices) and surround ourselves with them using IOT. What if there was a way this new network brought world’s best resources and knowledge, as a normal part of life ?

To overcome the digital information explosion in both life sciences and medical field, the Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.

LPBI (previously an equity sharing, non-profit entity) is now making its intellectual and digital intellectual properties available for sale to outside entities that are willing to take over and extend our reach. Tracking new information and discoveries, while creating new paths for current issues in biology, chemistry, medicine and therapeutics.

Aided by artificial intelligence and neurolinguistic programming LPBI has created its own curation process which includes synthesis, analysis, and interpretation of complex medical and scientific areas as well as various audio podcasts of Key Opinion Leaders.

The symbiotic nature of LPBI group allows us to respond to the needs of our scientific audiences, guarding against information obsolescence and overload, through innovative digital technologies and solutions, via:

• An open-access online scientific journal
• A series of 16 BioMed e-books.
• Real-time press coverage with real-time Twitter posting of speakers quotes during conferences.

Our resources have been widely accessible to the scientific and non-research community by the Open Access feature of LPBI’s Journal’s website  PharmaceuticalIntelligence.com.

• Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications

My proposed Elevator Pitch

• Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

My proposed Elevator Pitch

• We are in the higher digital-healthcare / electronic-healthcare arena a growing market of multiple unicorns, and a field that is in the rise. Our niche is trendy, high valued field, current trends are well known also to us. We understand the market as well as the scientific arena
• We bring to the market the second opinion concept that is working in heath care for so many years to the scientific research for pharmaceutical R&D, medical and life science education.
• We also offer a synthetic approach for the presented science and current knowledge as known and understood by the expert in his subject matter.
• LPBI’s future will be in AI, ML, NLP – contextual Medical Text Analysis, digital-medicine and digital education
• We solve the problem of attention in a tsunami of publication and research done and help increase productivity of R&D workers, analysts, academic researchers, IP workers, regulators, and healthcare providers.
• We are showing traction and well known multiple monetization strategies https://pharmaceuticalintelligence.com/vision/
• We can base our projections on a solid well know business model in the industry: “Pay for scientific content.”

George N. Gamota, Jr. – External Business Relations

The company is a multimedia publishing company, specializing in making available unique, curated, peer reviewed life science, medical and pharmaceutical research information of interest to whom?.  Its unique repository of data includes: X, Y, and Z, via print, e-articles, e-books, podcasts, etc.